創世紀(300083.SZ):宇樹科技爲公司在人形機器人領域重要的長期合作客戶之一
格隆匯3月3日丨創世紀(300083.SZ)近日在線上電話會議上表示,2022年至今,公司已向宇樹科技持續供貨,雙方已建立良好合作關係,其也成爲公司在人形機器人領域重要的長期合作客戶之一;未來,公司密切關注人形機器人領域發展趨勢,針對市場趨勢及客戶需求進行相關創新技術和產品研發,致力於爲目標市場客戶提供具有競爭力的產品和方案,未來如有更多客戶合作進展,公司將按相關規定及時履行信息披露義務。此外,提醒投資者目前該類客戶佔公司整體營收的比例較小,對公司業績不形成重大影響,未來也需要看行業的發展及公司持續研發投入,具有不確定性,請投資者注意風險,理性投資。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.